Shanghai - Delayed Quote CNY
Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
8.05
-0.18
(-2.19%)
At close: 3:00:03 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Weiyi Shen | Vice Chairman & GM | -- | -- | 1980 |
| Mr. Junfeng Guo | Financial Director | -- | -- | 1985 |
| Mr. Chao Sun | Board Secretary | -- | -- | 1987 |
| Mr. Chaoyang Yao | Deputy General Manager | -- | -- | 1980 |
| Mr. Chun Ye | Deputy General Manager | -- | -- | 1979 |
| Haiyasheng Li | Accounting Supervisor | -- | -- | -- |
Zhejiang Starry Pharmaceutical Co.,Ltd.
Modern Industrial Cluster Area
No. 9 West Fengxi Road Xianju County
Taizhou, 317306
China
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 1,845
Description
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products, such as levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is headquartered in Taizhou, China.
Corporate Governance
Zhejiang Starry Pharmaceutical Co.,Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
September 9, 2024 at 12:00 AM UTC
Ex-Dividend Date